Baird analyst Joe Vruwink raised the firm’s price target on Definitive Healthcare (DH) to $4 from $3 and keeps a Neutral rating on the shares. The firm updated its model following Q2 results and where its outlook was nudged higher.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DH:
- Cautious Optimism for Definitive Healthcare Corp Amid Market Strategy Revitalization and Customer Retention Challenges
- Definitive Healthcare Reports Q2 2025 Results
- Definitive Healthcare narrows FY25 adjusted EPS view to 22c-23c from 20c-23c
- Definitive Healthcare reports Q2 adjusted EPS 7c, consensus 5c
- Definitive Healthcare sees Q3 EPS 5c-6c, consensus 6c